FDA designates TERN-701 as breakthrough therapy for heavily pretreated Ph+ CP-CML, as allosteric BCR-ABL inhibitor shows ...

Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. In this type of cancer, the bone marrow produces too many white blood cells. If the disease isn’t effectively treated, it ...

Newly published data suggests most patients are opting for second- or third-generation tyrosine kinase inhibitors instead of a generic form of imatinib. Patients with chronic myelogenous leukemia (CML ...

The National Comprehensive Cancer Network announces funding for selected quality improvement research projects to utilize digital tools for improving decision-making and quality of life for people ...

An advocate discusses vital patient-provider conversations to promote the best care for individuals with chronic myeloid leukemia. Receiving a diagnosis of chronic myeloid leukemia (CML) can be ...

Articles published in this focus collection were selected from recent issues of Leukemia. They highlight new developments in our understanding and management of persons with CML. CML was the first ...

The use of tyrosine-kinase inhibitors (TKIs) in chronic myeloid leukaemia (CML) is one of the greatest single advances in the targeted treatment of cancer but, in most cases, TKI therapy suppresses ...

Please provide your email address to receive an email when new articles are posted on . It has been eight years since imatinib was approved as the first oral tyrosine kinase inhibitor indicated for ...

LONDON--(BUSINESS WIRE)--The global chronic myelogenous leukemia (CML) therapeutics market size is poised to grow by USD 1.74 billion during 2019-2023, according to a new report by Technavio, ...

Enliven Therapeutics Inc. (NASDAQ:ELVN) is one of the 11 Stocks With 3x-5x Returns This Year. Enliven Therapeutics has seen its stock price soar by 194 percent year-to-date, at $45.34 versus $15.40 on ...